Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

S0820, Adenoma and Second Primary Prevention Trial

Major Program

NCI Community Oncology Research Program

Research Group

Community Oncology and Prevention Trials

Status

Active, not recruiting

NCT ID

NCT01349881

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

Intervention

Eflornithine placebo & sulindac, Eflornithine placebo & sulindac placebo, Eflornithine plus sulindac, eflornithine & sulindac placebo

Condition

Colorectal Neoplasms

Investigators

Jason A. Zell, D.O., MPH

See list of participating sites